NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

Not Yet RecruitingPhase 3

Sponsor: Bristol-Myers Squibb

Conditions: Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis

Interventions: Deucravacitinib

This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.

Eligibility overview

Sex: ALL

Age: 4 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participants must have completed qualifying parent study through the protocol required treatment period. Qualifying studies include IM011-246, IM011-247, IM011-1069, IM011-126, IM011-1128, and IM011-1071.

Exclusion Criteria:

* Participants must not have any disease or medical condition that, in the opinion of the physician, would make them unsuitable for this protocol, would interfere with the interpretation of their safety or considered unsuitable by the physician for any other reason.

Other protocol-defined inclusion/exclusion criteria apply.